Quantitative Risk–Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease-Reference-Cited by-同舟云学术

Quantitative Risk–Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease

Published:2015-10-14 Issue:4 Volume:39 Page:295-305
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Saf

Author:

Bennett William E.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Link

http://link.springer.com/content/pdf/10.1007/s40264-015-0349-x.pdf

Reference64 articles.

1. National Health Information Survey—Use of Complementary Health Approaches in the United States [cited 2015 September 1, 2015]. Available from: https://nccih.nih.gov/research/statistics/NHIS/2012/natural-products/biotics .

2. Joint FAO/WHO Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario: April 30 and May 1, 2002.

3. Rogers NJ, Mousa SA. The shortcomings of clinical trials assessing the efficacy of probiotics in irritable bowel syndrome. J Altern Complement Med. 2012;18(2):112–9 (PubMed PMID: 22339099).

4. Boyle RJ, Robins-Browne RM, Tang ML. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256–64 (quiz 446–7. PubMed PMID: 16762934).

5. Degnan FH. The US Food and Drug Administration and probiotics: regulatory categorization. Clin Infect Dis. 2008;46(Suppl 2):S133–6 (discussion S44–51. PubMed PMID: 18181719).

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Probiotics an emerging therapeutic approach towards gut-brain-axis oriented chronic health issues induced by microplastics: A comprehensive review;Heliyon;2024-06

2. A Comprehensive Review of Oral Probiotic Supplementation in Adults: Implications for Inflammatory Bowel Disease;2023-11-14

3. Probiotics in Inflammatory Bowel Disease;2023-07-10

4. Preclinical evidence of probiotics in ulcerative colitis: a systematic review and network meta-analysis;Frontiers in Pharmacology;2023-06-09

5. Available Methods for Benefit-risk Assessment: Lessons for Inflammatory Bowel Disease Drugs;Journal of Crohn's and Colitis;2022-08-11